Reloxa Dosage/Direction for Use

Adults and Elderly: Severe (erosive or ulcerative) gastroesophageal reflux disease: The usual dose of Rabeprazole sodium is 20 mg once daily for 4 to 8 weeks; a further 8-week course may be needed for healing of erosive oesophagitis. Thereafter, maintenance therapy can be continued with 10 or 20 mg daily depending on the response. For symptomatic disease without erosive or ulcerative oesophagitis a dose of 10 or 20 mg may be given once daily for 4 weeks.
Active peptic ulcer disease: 20 mg daily is given for 4 to 8 weeks for duodenal ulcer and 6 to 12 weeks for gastric ulcer. For the eradication of Helicobacter pylori, Rabeprazole sodium may be combined with two antibacterials in a 1-week triple therapy regimen.
Effective regimens include 20 mg twice daily combined with clarithromycin 500 mg twice daily and amoxicillin 1 g twice daily, or combined with clarithromycin 250 mg twice daily and metronidazole 400 mg twice daily.
Zollinger-Ellison syndrome: The starting dose is 60 mg once daily, adjusted according to response. Doses up to 120 mg daily have been given; when the daily dose is more than 100 mg it should be given in 2 divided doses.
Children: Rabeprazole sodium (Reloxa) is not recommended for use in children, as there is no experience of its use in this group.
Renal and Hepatic Impairment: No dosage adjustment is necessary for patients with renal or hepatic impairment. Caution is however advised when Rabeprazole sodium (Reloxa) is first initiated in patients with severe hepatic dysfunction.